[{"id":"11327aff-f659-4a2a-a182-dea208387fae","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=cfcb5084798947a1ab082217be41540c","created_at":"2026-06-27T02:09:26.770Z","updated_at":"2026-06-27T02:09:26.770Z","phase":"Phase 2/3","brief_title":"Phase II/III clinical trial of loneribumab in combination with platinum-based chemotherapy ± bevacizumab as first-line treatment for patients with advanced, persistent, recurrent/metastatic cervical cancer.","source_id_and_acronym":"CTR20242664","lead_sponsor":"Shandong New Era Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • rulonilimab (F520)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 09/26/2024","start_date":" 09/26/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"300776a1-5c98-4d58-b7f2-c7165708c8d0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=79fd136aad734dd19b8ff754a2327da3","created_at":"2026-06-27T02:12:28.549Z","updated_at":"2026-06-27T02:12:28.549Z","phase":"Phase 1","brief_title":"A phase 1 study evaluating BGB-B2033 monotherapy and in combination with or without bevacizumab in patients with advanced or metastatic solid tumors.","source_id_and_acronym":"CTR20242917","lead_sponsor":"Guangzhou BeiGene Biopharmaceutical Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/11/2024","start_date":" 09/11/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"5d7c1a3b-1b04-4037-88d1-9974f258bdd7","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ea710524b3544fed95df60e6a3a8de97","created_at":"2026-06-27T02:01:17.040Z","updated_at":"2026-06-27T02:01:17.040Z","phase":"Phase 3","brief_title":"A study evaluating mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab monotherapy as maintenance therapy in patients with ovarian, fallopian tube, or peritoneal cancer who have received second-line platinum-based chemotherapy plus bevacizumab.","source_id_and_acronym":"CTR20241552","lead_sponsor":"ImmunoGen, Inc. / Hangzhou Sino-American East China Pharmaceutical Co., Ltd. / BSP Pharmaceuticals S.p.A. / PCI Pharma Services","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/20/2024","start_date":" 09/20/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"61fcec0f-b1b1-4224-8038-791e1a866673","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bf9a70dd5c384843988a85d3882acd17","created_at":"2026-06-27T02:26:15.169Z","updated_at":"2026-06-27T02:26:15.169Z","phase":"Phase 1/2","brief_title":"Clinical studies on the efficacy and safety of RC148 injection monotherapy and combination regimens in patients with locally advanced unresectable or metastatic malignant solid tumors.","source_id_and_acronym":"CTR20232413","lead_sponsor":"Rongchang Biopharmaceutical (Yantai) Co., Ltd.","biomarkers":" HER-2 • MSLN","pipe":" | ","alterations":" HER-2 expression • MSLN expression","tags":["HER-2 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • docetaxel • Aidixi (disitamab vedotin) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 221","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"622acea4-4cd2-404a-90ec-844ae0bf4053","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=221579f2758546b29c99994e1e6c54c7","created_at":"2026-06-27T02:26:04.810Z","updated_at":"2026-06-27T02:26:04.810Z","phase":"Phase 1/2","brief_title":"Phase IB/II clinical study of the safety, tolerability, and efficacy of SHR-A1811 injection in combination with antitumor drugs in patients with advanced solid tumors.","source_id_and_acronym":"CTR20232390","lead_sponsor":"Suzhou Shengdiya Biomedical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Irene (pyrotinib) • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6608ee73-bf22-4c1f-a971-34cb6ff8f3c7","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=dc6d584c93e74ed8bec5c5a5728e82b1","created_at":"2026-06-27T02:26:06.401Z","updated_at":"2026-06-27T02:26:06.401Z","phase":"Phase 3","brief_title":"A Phase II/III study on the safety and efficacy of BAT1308 in combination with platinum-based chemotherapy ± bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer with PD-L1 positivity (CPS ≥ 1).","source_id_and_acronym":"CTR20232394","lead_sponsor":"Bio-Thera Solutions, Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"6cf17c33-3020-4ad1-8dc8-b75be908ca63","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=209922557c87436497e8c555f788596d","created_at":"2026-06-27T02:24:52.692Z","updated_at":"2026-06-27T02:24:52.692Z","phase":"Phase 3","brief_title":"A randomized, controlled, open-label, multicenter phase III clinical trial evaluating the efficacy and safety of tolametinib in combination with vemurafenib for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.","source_id_and_acronym":"CTR20232218","lead_sponsor":"Shanghai Kezhou Pharmaceutical Research \u0026 Development Co., Ltd. / Tianjin Binjiang Pharmaceutical Research \u0026 Development Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"abd9d82f-0e8b-4e38-ac3b-7923ddcb0cc6","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ac087fe96bad41bfb1b1655d020ab35d","created_at":"2026-06-27T02:12:21.545Z","updated_at":"2026-06-27T02:12:21.545Z","phase":"Phase 3","brief_title":"Socarzolizumab Phase III Clinical Trial for Cervical Cancer","source_id_and_acronym":"CTR20242900","lead_sponsor":"Zhaoke (Guangzhou) Oncology Drug Co., Ltd. / Wuxi WuXi Biologics Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Shan Ke Yu (socazolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 11/28/2024","start_date":" 11/28/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"ae90796c-19e1-4670-b7f8-2ad596a65e86","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=62024b5c88fc4d03aa7a10033b39c8ba","created_at":"2026-06-27T01:58:30.760Z","updated_at":"2026-06-27T01:58:30.760Z","phase":"Phase 3","brief_title":"A Phase Ib/III clinical study of SHR-A1904 in combination with other drugs for the treatment of CLDN18.2-positive advanced solid tumors.","source_id_and_acronym":"CTR20241158","lead_sponsor":"Shanghai Hengrui Medicine Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)"],"overall_status":"Recruiting","enrollment":" Enrollment 924","initiation":"Initiation: 07/16/2024","start_date":" 07/16/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"cd818a91-f2ad-450d-b605-cc0ab6bfe81a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=34288bb576a244a8aadf861d2debfad7","created_at":"2026-06-27T02:10:25.711Z","updated_at":"2026-06-27T02:10:25.711Z","phase":"Phase 3","brief_title":"Phase III clinical trial of chidamide in combination with sintilimab and bevacizumab for the treatment of patients with advanced microsatellite stable or mismatch repair intact (MSS/pMMR) colorectal cancer who have failed ≥2 lines of standard therapy.","source_id_and_acronym":"CTR20242806","lead_sponsor":"Shenzhen Chipscreen Biosciences Co., Ltd.","biomarkers":" EGFR • KRAS • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" KRAS wild-type","tags":["EGFR • KRAS • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 12/06/2024","start_date":" 12/06/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"275ead9d-ca6d-498b-b03d-3b863b8a4436","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d5652e40a4d54779859b6ddea766deee","created_at":"2026-06-27T02:47:18.588Z","updated_at":"2026-06-27T02:47:18.588Z","phase":"Phase 2","brief_title":"A phase Ib/II clinical study evaluating the safety, pharmacokinetics, and preliminary efficacy of QL1706 or QL1604 injection in combination with bevacizumab injection in patients with advanced hepatocellular carcinoma.","source_id_and_acronym":"CTR20222220","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"2f09a203-d5e7-49e6-be90-04dd942c98ef","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=21c50a738ff94c658081dde924863b7a","created_at":"2026-06-27T02:55:55.664Z","updated_at":"2026-06-27T02:55:55.664Z","phase":"Phase 3","brief_title":"A study comparing tucatinib in combination with trastuzumab and mFOLFOX6 as first-line treatment for HER2+ metastatic colorectal cancer with standard therapy.","source_id_and_acronym":"CTR20230081","lead_sponsor":"Seagen Inc. / Merck Research \u0026 Development (China) Co., Ltd. / Corden Pharma GmbH / Almac Clinical Services","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • RAS wild-type","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • loperamide"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/15/2023","start_date":" 04/15/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"5f6de55a-cf0f-42e8-943f-12a7bf7a514b","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ef571a6fd713424c94f319a962d2ec44","created_at":"2026-06-27T02:58:02.889Z","updated_at":"2026-06-27T02:58:02.889Z","phase":"Phase 1/2","brief_title":"Phase Ib/II clinical trial of SHR-A1811 injection in combination with dalciribine, fulvestrant, bevacizumab, or letrozole/anastrozole for the treatment of HER2-low-expressing breast cancer.","source_id_and_acronym":"CTR20230432","lead_sponsor":"Suzhou Shengdiya Biomedical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • AiRuiKa (camrelizumab) • fulvestrant • letrozole • anastrozole • trastuzumab rezetecan (SHR-A1811) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"6ca19f6c-5b14-41b9-afad-5ef27c0d0a0e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=1ebcdd03028e4eb1ac6c69f1a26bd636","created_at":"2026-06-27T03:01:14.892Z","updated_at":"2026-06-27T03:01:14.892Z","phase":"Phase 3","brief_title":"Anlotinib as a first-line treatment for colorectal cancer","source_id_and_acronym":"CTR20210940","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"71d16d6f-b4b6-4004-9e8a-e5e4b7f99e60","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d8cc21b4aea34aa69ef8aa483d93cd0e","created_at":"2026-06-27T02:36:02.621Z","updated_at":"2026-06-27T02:36:02.621Z","phase":"Phase 2","brief_title":"Phase II clinical trial of AK112 with or without AK117 in metastatic colorectal cancer","source_id_and_acronym":"CTR20221153","lead_sponsor":"Zhongshan Kangfang Biomedical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Idafang (ivonescimab) • ligufalimab (AK117)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 07/28/2022","start_date":" 07/28/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"93f98a7c-e05a-409b-ae53-1837bca8aa1e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=0c3f1d7e27db47519385d8c4c2a463dd","created_at":"2026-06-27T03:03:47.785Z","updated_at":"2026-06-27T03:03:47.785Z","phase":"Phase 3","brief_title":"AK104 plus platinum-based chemotherapy, with or without bevacizumab, is used as first-line treatment for persistent, recurrent, or metastatic cervical cancer.","source_id_and_acronym":"CTR20211380","lead_sponsor":"Kangfang Pharmaceutical Co., Ltd. / Zhongshan Kangfang Biopharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 09/11/2021","start_date":" 09/11/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"97740f01-6a61-47ba-a97e-48f66e064982","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a804c9b9ad25484c9211d85a587825a0","created_at":"2026-06-27T02:35:00.016Z","updated_at":"2026-06-27T02:35:00.016Z","phase":"Phase 2","brief_title":"Phase II clinical trial of SKB264 in combination with other treatments for patients with advanced or metastatic non-small cell lung cancer.","source_id_and_acronym":"CTR20220980","lead_sponsor":"Sichuan Kelun Biotech Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 426","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"9d75ceba-52ee-43cf-a27a-59468252c9f1","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2b0849e523df4446ac37f93f7e18d0d1","created_at":"2026-06-27T02:56:13.743Z","updated_at":"2026-06-27T02:56:13.743Z","phase":"Phase 3","brief_title":"Clinical study evaluating the efficacy and safety of SG001 injection combined with chemotherapy ± bevacizumab as first-line treatment for PD-L1-positive (CPS≥1) recurrent or metastatic cervical cancer.","source_id_and_acronym":"CTR20230132","lead_sponsor":"Shijiazhuang Zhongqi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Enshuxing (enlonstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 368","initiation":"Initiation: 02/08/2023","start_date":" 02/08/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"a77245ef-322c-40e7-aac6-b31cfc84eabd","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=950f00e4d607417d8338ce1724e16b72","created_at":"2026-06-27T02:41:21.398Z","updated_at":"2026-06-27T02:41:21.398Z","phase":"Phase 1/2","brief_title":"Phase I/II clinical study of ZG005 in combination with paclitaxel and platinum-based ± bevacizumab regimen in patients with advanced cervical cancer.","source_id_and_acronym":"CTR20234267","lead_sponsor":"Suzhou Zekjing Biopharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"b20bcb6f-0ef5-4440-84c3-4b1363b829ca","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ace72e58caf14e10a65f84eec5ebf99c","created_at":"2026-06-27T02:48:38.837Z","updated_at":"2026-06-27T02:48:38.837Z","phase":"Phase 3","brief_title":"A Phase III clinical trial comparing HX008 injection with chemotherapy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer.","source_id_and_acronym":"CTR20222431","lead_sponsor":"Lepu Biotechnology Co., Ltd. / Dingkang (Wuhan) Biopharmaceutical Co., Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"eb459b47-8285-4a50-84d9-6c7024b0863a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=03179010411a456fa6d0dbc8efeecfb3","created_at":"2026-06-27T02:56:49.886Z","updated_at":"2026-06-27T02:56:49.886Z","phase":"Phase 3","brief_title":"GLS-010 injection combined with platinum-based chemotherapy ± bevacizumab is the first-line treatment for persistent, recurrent/metastatic cervical cancer.","source_id_and_acronym":"CTR20230235","lead_sponsor":"Guangzhou Yuhang Biotechnology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"f4aae645-96c5-4e72-9c90-caec2f778ed2","acronym":"TRIBE","url":"https://clinicaltrials.gov/study/NCT07669610","created_at":"2026-06-27T02:28:23.057Z","updated_at":"2026-06-27T02:28:23.057Z","phase":"Phase 3","brief_title":"An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC","source_id_and_acronym":"NCT07669610 - TRIBE","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/01/2026","start_date":" 10/01/2026","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 03/30/2029","study_completion_date":" 03/30/2029","last_update_posted":"2026-06-25"},{"id":"0da6e0d7-f14d-4b36-835e-4a51bfb48a3b","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=42590a57519845bfb81cd56d3ee0023c","created_at":"2026-06-27T03:14:59.573Z","updated_at":"2026-06-27T03:14:59.573Z","phase":"Phase 3","brief_title":"SHR-1701 in combination with bevacizumab and platinum-based doublet therapy for non-small cell lung cancer","source_id_and_acronym":"CTR20212944","lead_sponsor":"Suzhou Shengdiya Biomedical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • pemetrexed • retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 561","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"86dcbaa4-a0f7-4722-b301-afe751349fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07479485","created_at":"2026-03-28T01:39:14.150Z","updated_at":"2026-03-28T01:39:14.150Z","phase":"Phase 1/2","brief_title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","source_id_and_acronym":"NCT07479485","lead_sponsor":"Lepu Biopharma Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2026-03-18"}]